HRP20090074T3 - 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses - Google Patents
3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychosesInfo
- Publication number
- HRP20090074T3 HRP20090074T3 HR20090074T HRP20090074T HRP20090074T3 HR P20090074 T3 HRP20090074 T3 HR P20090074T3 HR 20090074 T HR20090074 T HR 20090074T HR P20090074 T HRP20090074 T HR P20090074T HR P20090074 T3 HRP20090074 T3 HR P20090074T3
- Authority
- HR
- Croatia
- Prior art keywords
- psychoses
- schizophrenia
- cis
- treatment
- dihydrotetrabanezine
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516167.4A GB0516167D0 (en) | 2005-08-06 | 2005-08-06 | Pharmaceutical compounds |
| GB0516790A GB0516790D0 (en) | 2005-08-16 | 2005-08-16 | Pharmaceutical compounds |
| PCT/GB2006/002936 WO2007017654A1 (en) | 2005-08-06 | 2006-08-04 | 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090074T3 true HRP20090074T3 (en) | 2009-04-30 |
Family
ID=37400949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090074T HRP20090074T3 (en) | 2005-08-06 | 2009-02-06 | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110257220A1 (el) |
| EP (2) | EP2050451B1 (el) |
| JP (1) | JP2009504622A (el) |
| KR (1) | KR20080033500A (el) |
| AT (2) | ATE415968T1 (el) |
| AU (1) | AU2006277753B2 (el) |
| CA (1) | CA2620960A1 (el) |
| CY (1) | CY1108843T1 (el) |
| DE (1) | DE602006004009D1 (el) |
| DK (1) | DK1855677T3 (el) |
| ES (1) | ES2318771T3 (el) |
| HK (1) | HK1111083A1 (el) |
| HR (1) | HRP20090074T3 (el) |
| MX (1) | MX2008001549A (el) |
| NZ (1) | NZ566011A (el) |
| PL (1) | PL1855677T3 (el) |
| PT (1) | PT1855677E (el) |
| RS (1) | RS50807B (el) |
| RU (1) | RU2407743C2 (el) |
| SI (1) | SI1855677T1 (el) |
| WO (1) | WO2007017654A1 (el) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668689C (en) | 2006-11-08 | 2015-12-29 | Neurocrine Biosciences Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| US7897768B2 (en) | 2007-06-08 | 2011-03-01 | General Electric Company | Method for making tetrabenazine compounds |
| US8053578B2 (en) | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| EP3351247A1 (en) | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| EP2694573B1 (en) | 2011-04-01 | 2020-05-27 | 3M Innovative Properties Company | Films comprising triazine-based ultraviolet absorbers |
| EA201691512A1 (ru) | 2014-01-27 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 |
| CN113413385A (zh) * | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| KR20180075591A (ko) | 2015-10-30 | 2018-07-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 발베나진 염 및 그의 다형체 |
| HUE059065T2 (hu) | 2015-12-23 | 2022-10-28 | Neurocrine Biosciences Inc | Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| CA3051832A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| TW201919622A (zh) | 2017-09-21 | 2019-06-01 | 美商紐羅克里生物科學有限公司 | 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組 |
| US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EA202090932A1 (ru) | 2017-10-10 | 2021-05-20 | Нейрокрин Байосайенсиз, Инк | Способы введения некоторых vmat2-ингибиторов |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US2830993A (en) | 1958-04-15 | Quinolizine derivatives | ||
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
-
2006
- 2006-08-04 AT AT06765238T patent/ATE415968T1/de active
- 2006-08-04 DE DE602006004009T patent/DE602006004009D1/de active Active
- 2006-08-04 AT AT08170385T patent/ATE534391T1/de active
- 2006-08-04 RS RSP-2009/0055A patent/RS50807B/sr unknown
- 2006-08-04 MX MX2008001549A patent/MX2008001549A/es active IP Right Grant
- 2006-08-04 RU RU2008108623/04A patent/RU2407743C2/ru not_active IP Right Cessation
- 2006-08-04 US US11/997,591 patent/US20110257220A1/en not_active Abandoned
- 2006-08-04 WO PCT/GB2006/002936 patent/WO2007017654A1/en active Application Filing
- 2006-08-04 AU AU2006277753A patent/AU2006277753B2/en not_active Expired - Fee Related
- 2006-08-04 EP EP08170385A patent/EP2050451B1/en active Active
- 2006-08-04 CA CA002620960A patent/CA2620960A1/en not_active Abandoned
- 2006-08-04 EP EP06765238A patent/EP1855677B1/en active Active
- 2006-08-04 PT PT06765238T patent/PT1855677E/pt unknown
- 2006-08-04 PL PL06765238T patent/PL1855677T3/pl unknown
- 2006-08-04 JP JP2008525620A patent/JP2009504622A/ja not_active Ceased
- 2006-08-04 DK DK06765238T patent/DK1855677T3/da active
- 2006-08-04 ES ES06765238T patent/ES2318771T3/es active Active
- 2006-08-04 NZ NZ566011A patent/NZ566011A/en not_active IP Right Cessation
- 2006-08-04 SI SI200630210T patent/SI1855677T1/sl unknown
- 2006-08-04 KR KR1020087005308A patent/KR20080033500A/ko not_active Application Discontinuation
-
2008
- 2008-05-20 HK HK08105580.7A patent/HK1111083A1/xx not_active IP Right Cessation
-
2009
- 2009-02-06 HR HR20090074T patent/HRP20090074T3/xx unknown
- 2009-02-26 CY CY20091100221T patent/CY1108843T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2050451B1 (en) | 2011-11-23 |
| EP1855677B1 (en) | 2008-12-03 |
| RU2407743C2 (ru) | 2010-12-27 |
| EP1855677A1 (en) | 2007-11-21 |
| RS50807B (sr) | 2010-08-31 |
| DE602006004009D1 (de) | 2009-01-15 |
| AU2006277753A1 (en) | 2007-02-15 |
| ATE415968T1 (de) | 2008-12-15 |
| CA2620960A1 (en) | 2007-02-15 |
| KR20080033500A (ko) | 2008-04-16 |
| WO2007017654A1 (en) | 2007-02-15 |
| DK1855677T3 (da) | 2009-02-09 |
| SI1855677T1 (sl) | 2009-04-30 |
| EP2050451A1 (en) | 2009-04-22 |
| JP2009504622A (ja) | 2009-02-05 |
| AU2006277753B2 (en) | 2011-11-10 |
| PT1855677E (pt) | 2009-01-13 |
| MX2008001549A (es) | 2008-04-04 |
| CY1108843T1 (el) | 2014-07-02 |
| PL1855677T3 (pl) | 2009-07-31 |
| RU2008108623A (ru) | 2009-09-20 |
| US20110257220A1 (en) | 2011-10-20 |
| NZ566011A (en) | 2011-01-28 |
| HK1111083A1 (en) | 2008-08-01 |
| ES2318771T3 (es) | 2009-05-01 |
| ATE534391T1 (de) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1111083A1 (en) | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses | |
| ZA200801170B (en) | 3,11B-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation | |
| AP2006003525A0 (en) | Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia. | |
| TW200612910A (en) | Medicaments comprising carbonyl compounds, and the use thereof | |
| IL173002A (en) | Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis | |
| ZA200604114B (en) | Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease | |
| PL1799231T3 (pl) | Zastosowanie cyklodekstryny do leczenia i zapobiegania chorobom zapalnym oskrzeli | |
| MX2007000224A (es) | Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos. | |
| HK1110025A1 (en) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility | |
| ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
| HRP20050075A2 (en) | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
| PT2366393E (pt) | Roflumilaste para o tratamento da hipertensão pulmonar | |
| MY140538A (en) | Substituted n-acyl-2-aminothiazoles | |
| IL186672A0 (en) | Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections | |
| TW200714284A (en) | Novel method | |
| ZA200800999B (en) | Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy | |
| MXPA05009243A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados. | |
| GB0513835D0 (en) | HIV inhibitors | |
| HRP20120434T1 (en) | 4-oxadiazolyl-piperidine compounds and use thereof |